Bone News and Research

RSS

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Hawthorn Pharmaceuticals, Inc. today announced a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer. The antibody portfolio targets a variety of cancers through the cell surface chondrotin sulfate proteoglycan 4 (CSPG4), which plays an important role in signaling pathways regulating tumor cell survival, growth, and motility.

17 May 2010

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S. Phase 2 catheter-based clinical trial to treat dilated cardiomyopathy (DCM). Treatment was performed by interventional cardiologist Timothy D. Henry, M.D., FACC, at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis, MN.

17 May 2010

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies, Inc. today announced its financial results for the first quarter 2010.

17 May 2010

Athersys presents data supporting MultiStem programs

Athersys, Inc. today presented data supporting its MultiStem® programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the area of obesity.

15 May 2010

Winners of 2010 IADR/GSK Innovation in Oral Care Awards announced

The International Association for Dental Research and GlaxoSmithKline Consumer Healthcare today announced the 2010 winners of the annual IADR/GSK Innovation in Oral Care Awards. The three prestigious awards recognize research in innovative oral care technologies that may maintain and improve oral health and the quality of life.

15 May 2010

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Amgen Inc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus Zometa® (zoledronic acid).

15 May 2010

SANUWAVE Health reports $3.0 million net loss for first-quarter 2010

SANUWAVE Health, Inc.,, an emerging medical technology company focused on regenerative medicine, today reported financial results for the three months ended March 31, 2010 and provided a business update.

14 May 2010

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

Interleukin Genetics, Inc. announced today financial and operational results for the first quarter ended March 31, 2010.

14 May 2010

Osteoporosis screening of women increased from 34% in 2001 to 64% in 2006: AHRQ

The proportion of women age 65 and over on Medicare who said that they had been screened for osteoporosis increased from 34 percent in 2001 to 64 percent in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

14 May 2010

Nephros reports 57% increase in revenues for first-quarter 2010

Nephros, Inc. announced today financial results for the three months ended March 31, 2010.

14 May 2010

Calcium deficiency may make people more prone to osteoporosis, obesity in later life: Study

There's no denying that people need calcium for strong, healthy bones. But new research from North Carolina State University suggests that not getting enough calcium in the earliest days of life could have a more profound, lifelong impact on bone health and perhaps even obesity than previously thought.

14 May 2010

Genta first-quarter net loss increases to $166.6 million

Genta Incorporated today announced financial results for the quarter ended March 31, 2010.

13 May 2010

27-year-old sickle cell disease patient undergoes multiple joint replacement surgery

Fortis Hospitals Mulund, Mumbai, performed a multiple joint replacement surgery on a 27 year old young Nigerian patient. Rebacca underwent a hip and a shoulder replacement surgery by Dr. Sachin Bhonsle, Consultant Orthopedic Surgeon, after years of suffering in pain and immobility.

13 May 2010

$High dose Vitamin D linked to high rate of fractures and falls$

High dose Vitamin D linked to high rate of fractures and falls

Many women have been regularly taking vitamin D supplements in the hope that it is good for their bones. However a new study has shown that high doses of this vitamin can actually increase the number of falls and fractures in older women.

12 May 2010

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.

12 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Mutation causing light chain amyloidosis identified

Light chain amyloidosis, a deadly protein misfolding disease, is caused by multiple mutations in cells that are intended to protect the body. Instead, the mutations send misfolded bundles of proteins through the bloodstream, potentially destroying the heart, kidneys, liver or other organs. Mayo Clinic researchers have identified one of these mutations and have shown that the molecule's shifting position is as important as its unique shape. The findings appear in the current issue of the journal Structure.

12 May 2010

Bone News and Research

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Emisphere Technologies first-quarter net loss increases to $18.5 million

Athersys presents data supporting MultiStem programs

Winners of 2010 IADR/GSK Innovation in Oral Care Awards announced

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

SANUWAVE Health reports $3.0 million net loss for first-quarter 2010

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

Osteoporosis screening of women increased from 34% in 2001 to 64% in 2006: AHRQ

Nephros reports 57% increase in revenues for first-quarter 2010

Calcium deficiency may make people more prone to osteoporosis, obesity in later life: Study

Genta first-quarter net loss increases to $166.6 million

27-year-old sickle cell disease patient undergoes multiple joint replacement surgery

High dose Vitamin D linked to high rate of fractures and falls

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Merck hosts R&D and Business Briefing

Mutation causing light chain amyloidosis identified

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News